Characteristics of macular edema in behcet disease after intravitreal bevacizumab injection

Abstract

Purpose:To investigate the effect of intravitreal bevacizumab (IVB) injection on macular edema (ME) secondary to Behcet's disease.Methods:This prospective case series included 15 patients with bilateral ME due to Behcet's disease. Intravitreal bevacizumab was injected into the more severely involved eye; the contralateral eye was evaluated as the control. Patients were followed up with comprehensive ocular examination, optical coherence tomography, and fluorescein angiography (FA) for a minimum of 6 months by a single ophthalmologist.Results:Patients with a mean age of 30.6 ± 7.4 years received a mean number of 3.3 IVB injections during the 6 months. The mean preinjection vision was 0.6 ± 0.3 and 0.4 ± 0.4 LogMAR in the case and control groups, respectively, with no significant improvement at 6 months. Mean central foveal thickness was 375.3 ± 132.1 and 307.2 ± 84.5 μm in the case and control groups, respectively, and these changed to 401 ± 199.9 (P = 0.65) and 307.7 ± 82.8 μm (P = 0.73) at month 6, respectively. A statistically nonsignificant improvement in ME was observed during the first 3 months in the case group. However, it did not persist up to month 6 on an as-needed basis. IVB injections caused a disproportionate decrease in the thickness of macular subfields. A reduction in disc leakage was observed on FA (P = 0.058). Logistic regression analysis revealed no statistically significant predictive factor for an improvement in visual acuity (VA) and a reduction in foveal thickness.Conclusion:During a 6-month period, IVB injections based on an as-needed protocol provided no statistically significant improvement in VA and ME.

Rare esophageal ulcers related to Behçet disease

“…BD is a chronic, recurrent multisystem inflammatory disorder that usually is characterized by recurrent oral aphthous ulcers, uveal infusion, genital ulcers, and cutaneous manifestations. [ 1 , 9 , 10 ] BD patients can also have symptoms including the gastrointestinal lesions, the central nervous system, vascular lesions, articular manifestations, pulmonary systems, cardiovascular systems, and renal systems. [ 11 ] However, the fundamental pathogenesis of BD is not still proven, and at present, there was no unified diagnostic criteria including serology or diagnostic tool for BD.…”

Outcomes of Intravenous Chemotherapy (Chemoreduction) for Retinoblastoma Based on Patient Age in 964 Eyes of 554 Patients

“…Regarding tumor laterality, in this series, we found older patients with less frequent germline mutation (57% vs. 51% vs. 38% vs. 38%) or bilateral involvement (90% vs. 86% vs. 81% vs. 73%). Ghassemi et al 9 reviewed 557 cases and found that the mean age at presentation was 24.7 months in germline cases and 35.7 months in nongermline cases. Likewise, prior studies have documented the mean age at diagnosis of bilateral retinoblastoma at approximately 12 months, whereas unilateral disease is diagnosed later at a mean age of 24 months 1 .…”

Novel approach to Behçet's disease in the era of biologic agents

“…Macular edema is a common finding in uveitic Behc ¸et's disease and can (in addition to uveitis) also be caused by retinal vein occlusion. Chroic macular edema is responsible for 42% of persistent visual lost in patients with Behc ¸et's disease [26,27]. Optic disc hyperemia and swelling may be associated with uveitis but can also develop in the event of raised intracranial pressure.…”